Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.
CONCLUSION: In patients with AF and an increased risk of stroke, prophylaxis with apixaban was highly cost-effective from the perspective of the Austrian health care system.
PMID: 32700584 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
More News: Atrial Fibrillation | Austria Health | Coumadin | European Medicines Agency (EMA) | Health Management | Heart Attack | Hemorrhagic Stroke | Ischemic Stroke | Pradaxa | Stroke | Vitamin K | Vitamins | Warfarin